10-K: Tango Therapeutics Reports Positive Clinical Data, Extends Runway

Tango Therapeutics, Inc. filed its annual 10-K report, highlighting positive clinical data for vopimetostat and TNG260, strategic collaborations, and a cash runway into 2028.

Summary

• Tango Therapeutics is a precision oncology company focused on developing targeted therapies for genetically altered cancers, leveraging synthetic lethality.
• Vopimetostat (TNG462) monotherapy showed clinical activity in MTAP-deleted cancers, with a median Progression-Free Survival (mPFS) of 7.2 months and 25% Objective Response Rate (ORR) in second-line pancreatic cancer, and a 9.1 months mPFS and 49% ORR in a histology-selective cohort (excluding sarcoma, pancreatic, and lung cancer).
• A registrational trial for vopimetostat in second-line MTAP-deleted pancreatic cancer is planned for initiation in 2026.
• Emerging data from the vopimetostat lung cancer cohort are consistent with expectations, with a safety and efficacy update anticipated in 2026.
• Vopimetostat is being evaluated in combination with Revolution Medicines' RAS(ON) inhibitors (daraxonrasib and zoldonrasib) in a Phase 1/2 trial, with 30 patients enrolled as of December 24, 2025, showing encouraging early efficacy and good tolerability.
• A clinical trial collaboration and supply agreement was signed with Erasca, Inc. in March 2026 to evaluate vopimetostat in combination with Erasca's pan-RAS molecular glue, ERAS-0015.
• TNG456, a brain-penetrant PRMT5 inhibitor for CNS cancers (focus on GBM), began enrolling patients in a Phase 1/2 trial in May 2025, with a safety and efficacy update expected in 2026.
• TNG260, a first-in-class CoREST inhibitor, demonstrated a mPFS of 29 weeks (n=5) in checkpoint inhibitor resistant STK11 mutant/KRAS wild-type NSCLC when combined with pembrolizumab, more than double the standard of care (~10 weeks).
• TNG961, a novel molecular glue targeting HBS1L for degradation in FOCAD-deleted/MTAP-deleted cancers, is in the IND-enabling phase of development.
• The company reported a net loss of $101.6 million for the year ended December 31, 2025, compared to $130.3 million in 2024.
• As of December 31, 2025, the accumulated deficit was $603.2 million.
• Cash, cash equivalents, and marketable securities totaled $343.1 million as of December 31, 2025, with an additional $62.1 million raised through an 'at-the-market' offering program by March 2, 2026.
• Existing capital is expected to fund operating expenses and capital expenditure requirements into 2028.
• The research term of the collaboration agreement with Gilead Sciences was mutually truncated in August 2025, concluding research activities, but future milestones and royalties remain in effect. $53.8 million in deferred revenue was recognized in Q3 2025 as a result.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing as moderately positive. The strong early clinical data for vopimetostat and TNG260, coupled with a solid cash runway into 2028 and strategic collaborations, indicate promising pipeline progression. However, the ongoing significant net losses and the discontinuation of two programs highlight the inherent risks and early stage of the company's development.

Positives

• Vopimetostat (TNG462) monotherapy demonstrated positive clinical activity in MTAP-deleted pancreatic cancer (mPFS 7.2 months, 25% ORR) and a histology-selective cohort (mPFS 9.1 months, 49% ORR), supporting a planned registrational trial in 2026.
• Vopimetostat showed a favorable safety and tolerability profile with no drug-related dose discontinuations and ~8% dose reduction at 250 mg QD.
• Early efficacy data from the vopimetostat combination trial with Revolution Medicines' RAS(ON) inhibitors are encouraging, with both combinations well-tolerated.
• TNG260 in combination with pembrolizumab achieved a median Progression-Free Survival (mPFS) of 29 weeks in checkpoint inhibitor resistant STK11 mutant/KRAS wild-type NSCLC, more than double the standard of care (~10 weeks).
• The company has a strong cash position of $343.1 million as of December 31, 2025, supplemented by $62.1 million in Q1 2026, providing a cash runway into 2028.
• Strategic collaborations with Revolution Medicines, Erasca, and Eli Lilly enhance pipeline development and potential combination therapies.
• TNG456, a brain-penetrant PRMT5 inhibitor, is advancing in Phase 1/2 clinical trials with initial pharmacokinetics supporting its CNS penetration hypothesis.

Negatives

• The company has incurred significant net losses since inception, with an accumulated deficit of $603.2 million as of December 31, 2025.
• Development of the TNG348 program was discontinued in May 2024 due to liver toxicity observed in its Phase 1/2 clinical trial.
• Development of the TNG908 program was discontinued in November 2024 due to insufficient brain exposure for clinical activity in GBM and portfolio prioritization.
• The company has no products approved for commercial sale and has not generated any revenue from product sales to date, with profitability not expected in the foreseeable future.
• Reliance on a limited number of third-party Contract Development and Manufacturing Organizations (CDMOs), including a sole supplier for active pharmaceutical ingredients (API) affiliated with WuXi AppTec, poses supply chain risks, especially given proposed Congressional legislation targeting WuXi AppTec.

Risks

• The company has a limited operating history and no products approved for commercial sale, with no revenue from product sales to date and may never become profitable.
• Significant net losses are expected to continue for the foreseeable future, and operating results may fluctuate significantly.
• Substantial additional funding will be needed; inability to raise capital on acceptable terms could force delays or elimination of product development programs or commercialization efforts, and may cause dilution to stockholders or require relinquishing rights.
• Uncertainty of clinical trial success, with no successful completion of large-scale pivotal clinical trials to date, and programs still in preclinical development may never advance.
• Focus on genetically defined or biomarker-driven cancers is a rapidly evolving area, and the novel drug discovery approach may not lead to approved or marketable products.
• Inability to successfully validate, develop, and obtain regulatory approval for screening and companion diagnostic tests, or significant delays, could hinder commercial potential.
• Clinical product development is lengthy, expensive, and has an uncertain outcome, with initial, interim, and top-line data subject to change and not necessarily predictive of final results.
• Clinical trials may reveal significant adverse events not seen in preclinical studies, leading to safety profiles that inhibit regulatory approval or market acceptance.
• Product candidates modulating novel pathways or utilizing novel binding locations may incur greater R&D expenses, regulatory issues, or unknown adverse effects.
• Delays or failure to obtain required regulatory approvals will materially impair the ability to commercialize product candidates and generate revenue.
• Public health crises may materially and adversely affect business, financial results, and disrupt clinical trial development and completion.
• Reliance on third parties to conduct clinical trials and for manufacturing increases risks of non-compliance, missed deadlines, and insufficient supply.
• Inability to obtain new patents, maintain existing patents, or protect trade secrets could harm business and competitive position.
• Infringement of third-party patents could lead to damages, licensing costs, or prevention of manufacturing/sale of products.
• Development of combination therapies may present more complex challenges than single-agent therapies, including demonstrating contribution of each component and regulatory hurdles.
• Inadequate funding for government agencies (e.g., FDA, SEC) could delay regulatory processes and impact business operations.
• Unfavorable global economic conditions, including inflation and interest rate increases, could adversely affect business, financial condition, or results of operations.
• The company's principal stockholders own a significant percentage of stock, potentially exerting significant control over stockholder approval matters.
• Ability to utilize net operating loss carryforwards and other tax attributes may be limited due to ownership changes or regulatory changes.
• Anti-takeover provisions in charter documents and Delaware law could make an acquisition more difficult.
• Bylaws designate specific courts as exclusive forums for certain litigation, potentially limiting stockholders' ability to choose a favorable judicial forum.
• Exposure to U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations, with potential for serious consequences for violations.
• Risk of employees, principal investigators, CROs, and consultants engaging in misconduct or improper activities, including non-compliance with regulatory standards and insider trading.
• Inability to adequately protect information technology systems from cyberattacks, cyber intrusions, or unauthorized disclosure of confidential/proprietary information, including personal data.
• Risks and challenges associated with the use of artificial intelligence (AI), including cybersecurity, privacy, intellectual property, and regulatory compliance.

Future Outlook

Tango Therapeutics anticipates initiating a registrational trial for vopimetostat in second-line MTAP-deleted pancreatic cancer in 2026. Clinical data updates for the vopimetostat lung cohort and initial data from the vopimetostat combination trial with RAS(ON) inhibitors are expected in 2026. A safety and efficacy update for TNG456 is also anticipated in 2026. The company expects to continue incurring significant operating losses for the foreseeable future as it advances its product candidates through clinical development and seeks regulatory approvals. Existing cash, cash equivalents, and marketable securities are projected to fund operating expenses and capital expenditure requirements into 2028.

Management Comments

• "We are a precision oncology company with a limited operating history. We have no products approved for commercial sale, have not generated any revenue from product sales and may never become profitable."
• "We have incurred significant net losses since our inception and anticipate that we will continue to incur losses for the foreseeable future."
• "We will need to raise substantial additional funding. If we are unable to raise capital when needed or on terms acceptable to us, we would be forced to delay, reduce or eliminate some of our product development programs or commercialization efforts."
• "We believe that our existing cash, cash equivalents and marketable securities on hand as of December 31, 2025 will enable us to fund our operating expenses and capital expenditure requirements at least into 2028."
• "We believe our approach will provide the ability to deliver deep, durable target inhibition with favorable tolerability and safety profiles, thus potentially maximizing clinical benefit."
• "The differentiated profile of vopimetostat enabling the potential for efficacious and tolerable RAS inhibitor combinations, in March 2026, we entered into a clinical trial collaboration and supply agreement (CTCSA) with Erasca, Inc., or Erasca, to evaluate vopimetostat in combination with Erascas pan-RAS molecular glue, ERAS-0015."
• "We believe that the initial pharmacokinetics from the clinical trial support our hypothesis that TNG456 will reach efficacious exposures in the CNS at well-tolerated doses."
• "We are committed to implementing governance and control measures to mitigate these risks, but there can be no assurance that such measures will adequately prevent or mitigate the adverse effects that the integration and use of AI may have on our business, financial condition and results of operations."

Industry Context

StockSavvy.ai notes that Tango Therapeutics operates in the highly competitive and capital-intensive precision oncology sector, focusing on synthetic lethality, a strategy gaining traction with the success of PARP inhibitors. The company's pipeline, particularly its MTA-cooperative PRMT5 inhibitors (vopimetostat, TNG456) and CoREST inhibitor (TNG260), targets genetically defined cancers, aligning with a broader industry trend towards personalized medicine. The collaborations with Revolution Medicines and Erasca for RAS inhibitor combinations are strategic moves to address significant unmet needs in pancreatic and lung cancers, where RAS mutations are prevalent. The discontinuation of TNG348 and TNG908 reflects the high attrition rate inherent in early-stage drug development, a common challenge across the biopharmaceutical industry. The company's reliance on a sole API supplier, WuXi AppTec, introduces geopolitical and supply chain risks, a growing concern for many global pharmaceutical companies.

Comparison to Industry Standards

• Vopimetostat's mPFS of 7.2 months and 25% ORR in 2L MTAP-deleted pancreatic cancer is noted as more than double that observed in historical chemotherapy studies (~10% ORR), suggesting a potentially superior efficacy profile compared to current standard of care in this specific patient population.
• The 29-week mPFS for TNG260 plus pembrolizumab in STK11 mutant/KRAS wild-type NSCLC is more than double the standard of care PFS of ~10 weeks, indicating a significant improvement over existing therapies for this difficult-to-treat subgroup.
• The favorable safety and tolerability profile of vopimetostat, with no drug-related dose discontinuations and ~8% dose reduction at 250 mg QD, positions it as a potentially best-in-class molecule compared to other PRMT5 inhibitors that have faced dose-limiting toxicities.
• The discontinuation of TNG348 due to liver toxicity and TNG908 due to insufficient brain exposure are consistent with the high failure rates in oncology drug development, where many compounds initially showing promise in early stages fail due to safety or efficacy issues, similar to experiences seen with other biopharmaceutical companies.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently a party to any litigation or legal proceedings that, in management's opinion, are probable to have a material adverse effect on its business.

Related Party Transactions

• In August 2023, the company received an inconsequential equity stake in Sesame Therapeutics, Inc. (a related party) in exchange for providing lab space and resources. An observable price change event in 2025 resulted in a $0.5 million increase in fair value.
• In June 2024, the company granted Sesame Therapeutics, Inc. a non-exclusive license to certain know-how associated with preclinical research for a $0.1 million upfront payment. The company is eligible for up to $25.9 million in potential future milestones and low single-digit tiered royalties.
• In August 2025, the company and Sesame Therapeutics, Inc. entered into a use and occupancy sub-lease of office and laboratory space at 201 Brookline Avenue, with total sub-lease payments approximating $0.4 million over the term.
• In November 2024, the company and Revolution Medicines, Inc. (RevMed) entered into a Clinical Trial Collaboration and Supply Agreement (CTCSA) for daraxonrasib and zoldonrasib, with RevMed supplying compounds at no cost. This is considered a related party transaction due to common relationships amongst management and board members.
• In October 2025, the company and Malte Peters, M.D. (who also served on the Board of Directors) entered into a consulting agreement. Dr. Peters received monthly compensation of $36,000 and an equity grant of 150,000 non-qualified stock options. This is deemed a related party transaction.

Stakeholder Impact

• **Shareholders**: Positive clinical data for lead candidates and extended cash runway could increase investor confidence. However, ongoing net losses, program discontinuations, and potential dilution from future capital raises pose risks. Anti-takeover provisions and forum selection clauses may limit shareholder influence.
• **Employees**: The company's focus on talent acquisition, development, competitive benefits, and an inclusive culture aims to attract and retain high-quality personnel. Management changes, such as the appointment of a new CEO, could impact organizational dynamics.
• **Customers (Patients)**: The development of precision oncology therapies for genetically defined cancers addresses high unmet medical needs, potentially offering new treatment options for patients with pancreatic, lung, and CNS cancers.
• **Suppliers/Contractors**: Continued reliance on a limited number of third-party manufacturers and CROs, particularly the sole API supplier affiliated with WuXi AppTec, creates dependency and potential supply chain vulnerabilities. The termination of the Medivir Agreement impacts a previous partner.
• **Creditors**: The company's significant accumulated deficit and reliance on future financing indicate a need for continued capital, which could be a consideration for creditors, though the current cash runway provides stability into 2028.

Next Steps

• Initiate a registrational trial for vopimetostat in second-line MTAP-deleted pancreatic cancer in 2026.
• Provide a safety and efficacy update from the lung cohort of the vopimetostat monotherapy clinical trial in 2026.
• Provide initial clinical data from the combination clinical trial evaluating vopimetostat with Revolution Medicines' RAS(ON) inhibitors in 2026.
• Provide a safety and efficacy update from the TNG456 Phase 1/2 clinical trial in 2026.
• Advance TNG961, a novel HBS1L degrader, through the IND-enabling phase of development.
• Continue dose expansion for TNG260 at 80 mg QD in STK11 mutant/KRAS wild-type NSCLC patients.
• Evaluate the development path for the vopimetostat histology selective cohort and selected indications as stand-alone development opportunities.
• Initiate the combination of TNG456 with abemaciclib upon confirmation of single-agent TNG456 activity in GBM patients.
• Further expand and diversify the supply chain by identifying and contracting other CDMOs for drug substance and drug product manufacturing, especially given risks associated with current sole suppliers.

Key Dates

Recommendation

The filing presents a mixed but generally positive outlook for Tango Therapeutics. The strong early clinical data for vopimetostat and TNG260, particularly the efficacy signals exceeding historical standards in challenging cancer types, are significant positives that could drive future value. The extended cash runway into 2028 provides crucial operational flexibility. However, the company remains in early-stage development with no commercial products, continues to incur substantial losses, and has experienced program discontinuations (TNG348, TNG908). The reliance on a sole API supplier (WuXi AppTec) introduces a notable geopolitical and supply chain risk. Given the promising clinical progress balanced against the inherent risks of biopharmaceutical development and ongoing losses, a 'hold' recommendation is appropriate for a seasoned investor. It acknowledges the potential upside from pipeline advancements while recognizing the considerable execution risks and long path to profitability.

Keywords

Precision Oncology, Synthetic Lethality, Vopimetostat, TNG462, PRMT5 Inhibitor, MTAP-deleted Cancer, Pancreatic Cancer, Lung Cancer, Glioblastoma, TNG456, Brain-Penetrant, TNG260, CoREST Inhibitor, STK11 Mutant NSCLC, RAS Inhibitors, Clinical Trials, Biotechnology, Pharmaceutical, SEC Filing, 10-K